<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02348762</url>
  </required_header>
  <id_info>
    <org_study_id>H-34686 Glutathione and Aging</org_study_id>
    <nct_id>NCT02348762</nct_id>
  </id_info>
  <brief_title>Energetics and Function in Older Humans</brief_title>
  <official_title>Energetics and Function in Older Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have previously reported that older patients with HIV are deficient in&#xD;
      glutathione (GSH) due to decreased availability of cysteine and glycine, and that oral&#xD;
      supplementation with cysteine (as n-acetylcysteine) and glycine for 2-weeks corrects their&#xD;
      own levels, and improves concentrations of red-cell GSH. The investigators also found that&#xD;
      when GSH deficient, subjects had impaired mitochondrial energetics and this improved with an&#xD;
      increase in intracellular GSH concentrations. The current proposal will investigate if&#xD;
      cysteine and glycine supplementation for a duration of 24 weeks will result in changes in :&#xD;
      (a) GSH levels; (b) body composition/anthropometry; (c) strength and function; (d) quality of&#xD;
      life; (e) mitochondrial energetics; (f) biochemistry (including dyslipidemia and oxidative&#xD;
      stress); (g) protein and glucose metabolism; (h) cognition and memory. 3 months after&#xD;
      completing supplementation, measurement of GSH concentrations, strength, function,&#xD;
      mitochondrial energetics and neurocognitive tests will be done to determine the effects of&#xD;
      washout.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data not available at present&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Red blood cell concentrations of Glutathione measured by HPLC</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Aging</condition>
  <condition>Erythrocyte Glutathione Deficiency</condition>
  <condition>Muscle Weakness</condition>
  <arm_group>
    <arm_group_label>Cysteine/glycine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Older subjects will be studied before and after taking oral cysteine (as n-acetylcysteine) and glycine for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cysteine (as n-acetylcysteine) and Glycine</intervention_name>
    <description>Older subjects will be studied before and after receiving cysteine and glycine</description>
    <arm_group_label>Cysteine/glycine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Older subjects:&#xD;
&#xD;
          -  age 70-80 years;&#xD;
&#xD;
        Younger subjects:&#xD;
&#xD;
          -  age 21-30 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No known diabetes, liver disease, kidney disease, coronary heart disease, stroke, or&#xD;
             cancer;&#xD;
&#xD;
          2. Any limitations in ability to walk;&#xD;
&#xD;
          3. Triglyceride concentrations greater than 500 mg/dl (if lipid lowering medications are&#xD;
             stopped);&#xD;
&#xD;
          4. BMI less than 20.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R V Sekhar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor Metabolic Research Unit (MRU)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>January 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2015</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Rajagopal V Sekhar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

